Interleukin 11, Recombinant, Human (Interleukin-11, IL-11, IL11, Adipogenesis Inhibitory Factor, AGIF, Oprelvekin)

Source:\nRecombinant corresponding to 179aa of human Interleukin-11 expressed in E.coli is a single, non-glycosylated polypeptide chain.\n\nMolecular Weight:\n~19.3kD\n\nBiological Activity:\nThe ED50 as determined by the dose-dependent stimulation of the proliferation of mouse 7TD1 was found to be less then 10ng/ml, corresponding to a Specific Activity of 1x10 IU/mg.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 0.95 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of IL-11 as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8433-03J

Size

2ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. Purification and characterization of recombinant truncated human interleukin-11 expressed as fusion protein in Escherichia coli. Biotechnol Lett 2005 Jul;27(13):905-10. 2. Expression of a bioactive recombinant human interleukin-11 in chicken HD11 cell line. Cytokine 2005 Jun 21;30(6):382-90. 3. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 2005 Jan;128(1):49-58. 4. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11). Int J Pharm 2004 Nov 22;286(1-2):53-67. 5. Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Radiat Res 2004 Aug;162(2):157-63. 6. A multiple-dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin-11 (oprelvekin). Biopharm Drug Dispos 2004 Oct;25(7):291-6.